【摘要】：目的:觀察利伐沙班治療肺栓塞患者的療效、安全性。方法:選取肺栓塞患者100例,按隨機(jī)數(shù)字表法分為觀察組和對(duì)照組,各50例。兩組患者均采用護(hù)理干預(yù)進(jìn)行康復(fù)治療,并于尿激酶20 000 IU/(kg·h),ivgtt,2 h溶栓治療。觀察組患者給予利伐沙班15 mg,bid,連續(xù)治療3周,3周后改為20 mg,qd。對(duì)照組患者給予低分子肝素鈣1 mg/kg,bid,聯(lián)合華法林鈉5 mg,qd,聯(lián)合給藥≥5 d后,至國(guó)際標(biāo)準(zhǔn)化比值(INR)為2~3時(shí),停用低分子肝素鈣,單獨(dú)口服華法林鈉。兩組療程均為3個(gè)月。觀察兩組患者臨床療效及治療前后氧分壓(PaO_2)、二氧化碳分壓(PaCO_2)、D-二聚體水平,并記錄咳嗽、胸痛、呼吸困難等臨床癥狀緩解情況及不良反應(yīng)發(fā)生率。結(jié)果:觀察組患者有效率(90.0%)顯著高于對(duì)照組(74.0%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者PaO_2、PaCO_2水平明顯高于治療前,D-二聚體水平明顯低于治療前,且觀察組變化幅度明顯大于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者咳嗽、胸痛、呼吸困難等臨床癥狀緩解率明顯高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者不良反應(yīng)發(fā)生率(12.0%)顯著低于對(duì)照組(30.0%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:利伐沙班輔以合理的護(hù)理干預(yù)能顯著提高肺栓塞患者的臨床療效,且不良反應(yīng)發(fā)生率低。
[Abstract]:Objective: to observe the efficacy and safety of rivashaban in the treatment of pulmonary embolism. Methods: 100 patients with pulmonary embolism were randomly divided into observation group (n = 50) and control group (n = 50). The patients in both groups were treated with nursing intervention and thrombolysis with urokinase 20 000 IU/ (kg 路h), ivgtt,2 h). The patients in the observation group were treated with rivasaban 15 mg,bid, for 3 weeks and changed to 20 mg,qd. after 3 weeks. The patients in the control group were given low molecular weight heparin calcium 1 mg/kg,bid, combined with warfarin sodium 5 mg,qd, for more than 5 days, and when the international standardized ratio (INR) was 2 鈮，

本文編號(hào)：2479366